Investments in vaccine manufacturing across Asia Pacific are driving demand for biopharmaceutical process analytical technology (PAT), as governments and pharmaceutical companies expand production capacity and strengthen pandemic preparedness, according to MarketsandMarkets. The research firm expects the global biopharmaceutical process analytical technology market to grow from $1.96b in 2026 to $4.32b by 2031, at a compound annual growth rate (CAGR) of 17.1%. Beyond vaccine manufacturing, demand for biopharmaceutical process analytical technology is being driven by the need for higher product quality, faster therapy development, stricter regulatory compliance, and greater manufacturing efficiency. By technology, analysers accounted for the largest market share at 38% in 2025. Online systems held the largest share by system type at 45%, whilst biosimilars and biologics represented the largest application segment with a 39.9% share.